Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Dirk J. de Jong is active.

Publication


Featured researches published by Dirk J. de Jong.


Nature Genetics | 2010

Genome-wide association identifies multiple ulcerative colitis susceptibility loci

Dermot McGovern; Agnès Gardet; Leif Törkvist; Philippe Goyette; Jonah Essers; Kent D. Taylor; Benjamin M. Neale; Rick Twee-Hee Ong; Caroline Lagacé; Chun Li; Todd Green; Christine Stevens; Claudine Beauchamp; Phillip Fleshner; Marie Carlson; Mauro D'Amato; Jonas Halfvarson; Martin L. Hibberd; Mikael Lördal; Leonid Padyukov; Angelo Andriulli; E. Colombo; Anna Latiano; Orazio Palmieri; Edmond Jean Bernard; Colette Deslandres; Daan W. Hommes; Dirk J. de Jong; Pieter Stokkers; Rinse K. Weersma

Ulcerative colitis is a chronic, relapsing inflammatory condition of the gastrointestinal tract with a complex genetic and environmental etiology. In an effort to identify genetic variation underlying ulcerative colitis risk, we present two distinct genome-wide association studies of ulcerative colitis and their joint analysis with a previously published scan, comprising, in aggregate, 2,693 individuals with ulcerative colitis and 6,791 control subjects. Fifty-nine SNPs from 14 independent loci attained an association significance of P < 10−5. Seven of these loci exceeded genome-wide significance (P < 5 × 10−8). After testing an independent cohort of 2,009 cases of ulcerative colitis and 1,580 controls, we identified 13 loci that were significantly associated with ulcerative colitis (P < 5 × 10−8), including the immunoglobulin receptor gene FCGR2A, 5p15, 2p16 and ORMDL3 (orosomucoid1-like 3). We confirmed association with 14 previously identified ulcerative colitis susceptibility loci, and an analysis of acknowledged Crohns disease loci showed that roughly half of the known Crohns disease associations are shared with ulcerative colitis. These data implicate approximately 30 loci in ulcerative colitis, thereby providing insight into disease pathogenesis.


Proceedings of the National Academy of Sciences of the United States of America | 2012

Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes

Johanneke Kleinnijenhuis; Jessica Quintin; Frank Preijers; Leo A. B. Joosten; Daniela C. Ifrim; Sadia Saeed; Cor Jacobs; Joke van Loenhout; Dirk J. de Jong; Hendrik G. Stunnenberg; Ramnik J. Xavier; Jos W. M. van der Meer; Reinout van Crevel; Mihai G. Netea

Adaptive features of innate immunity, recently described as “trained immunity,” have been documented in plants, invertebrate animals, and mice, but not yet in humans. Here we show that bacille Calmette-Guérin (BCG) vaccination in healthy volunteers led not only to a four- to sevenfold increase in the production of IFN-γ, but also to a twofold enhanced release of monocyte-derived cytokines, such as TNF and IL-1β, in response to unrelated bacterial and fungal pathogens. The enhanced function of circulating monocytes persisted for at least 3 mo after vaccination and was accompanied by increased expression of activation markers such as CD11b and Toll-like receptor 4. These training effects were induced through the NOD2 receptor and mediated by increased histone 3 lysine 4 trimethylation. In experimental studies, BCG vaccination induced T- and B-lymphocyte–independent protection of severe combined immunodeficiency SCID mice from disseminated candidiasis (100% survival in BCG-vaccinated mice vs. 30% in control mice). In conclusion, BCG induces trained immunity and nonspecific protection from infections through epigenetic reprogramming of innate immune cells.


PLOS Pathogens | 2005

NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis.

Gerben Ferwerda; Stephen E. Girardin; Bart Jan Kullberg; Lionel Le Bourhis; Dirk J. de Jong; Dennis M. L. Langenberg; Reinout van Crevel; Gosse J. Adema; Tom H. M. Ottenhoff; Jos W. M. van der Meer; Mihai G. Netea

Infection with Mycobacterium tuberculosis is one of the leading causes of death worldwide. Recognition of M. tuberculosis by pattern recognition receptors is crucial for activation of both innate and adaptive immune responses. In the present study, we demonstrate that nucleotide-binding oligomerization domain 2 (NOD2) and Toll-like receptors (TLRs) are two nonredundant recognition mechanisms of M. tuberculosis. CHO cell lines transfected with human TLR2 or TLR4 were responsive to M. tuberculosis. TLR2 knock-out mice displayed more than 50% defective cytokine production after stimulation with mycobacteria, whereas TLR4-defective mice also released 30% less cytokines compared to controls. Similarly, HEK293T cells transfected with NOD2 responded to stimulation with M. tuberculosis. The important role of NOD2 for the recognition of M. tuberculosis was demonstrated in mononuclear cells of individuals homozygous for the 3020insC NOD2 mutation, who showed an 80% defective cytokine response after stimulation with M. tuberculosis. Finally, the mycobacterial TLR2 ligand 19-kDa lipoprotein and the NOD2 ligand muramyl dipeptide synergized for the induction of cytokines, and this synergism was lost in cells defective in either TLR2 or NOD2. Together, these results demonstrate that NOD2 and TLR pathways are nonredundant recognition mechanisms of M. tuberculosis that synergize for the induction of proinflammatory cytokines.


Journal of Immunology | 2005

Nucleotide-Binding Oligomerization Domain-2 Modulates Specific TLR Pathways for the Induction of Cytokine Release

Mihai G. Netea; Gerben Ferwerda; Dirk J. de Jong; Trees Jansen; Liesbeth Jacobs; Matthijs Kramer; Ton Naber; Joost P. H. Drenth; Stephen E. Girardin; Bart Jan Kullberg; Gosse J. Adema; Jos W. M. van der Meer

The recognition of peptidoglycan by cells of the innate immune system has been controversial; both TLR2 and nucleotide-binding oligomerization domain-2 (NOD2) have been implicated in this process. In the present study we demonstrate that although NOD2 is required for recognition of peptidoglycan, this leads to strong synergistic effects on TLR2-mediated production of both pro- and anti-inflammatory cytokines. Defective IL-10 production in patients with Crohn’s disease bearing loss of function mutations of NOD2 may lead to overwhelming inflammation due to a subsequent Th1 bias. In addition to the potentiation of TLR2 effects, NOD2 is a modulator of signals transmitted through TLR4 and TLR3, but not through TLR5, TLR9, or TLR7. Thus, interaction between NOD2 and specific TLR pathways may represent an important modulatory mechanism of innate immune responses.


European Journal of Immunology | 2004

NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease.

Mihai G. Netea; Bart Jan Kullberg; Dirk J. de Jong; Barbara Franke; Tom Sprong; Ton Naber; Joost P. H. Drenth; Jos W. M. van der Meer

Mutations of the NOD2 gene have been associated with an increased susceptibility to Crohns disease, but the pathogenetic mechanisms mediated by NOD2 remain elusive. In the present study, we demonstrate that the 3020insC frameshift‐mutation in the NOD2 gene associated with Crohns disease results in defective release of IL‐10 from blood mononuclear cells after stimulation with the Toll‐like receptor (TLR)2 ligands, peptidoglycan and Pam3Cys‐KKKK, but not with bacterial LPS, a TLR4 ligand. The potential pathophysiological significance of this finding in patients with Crohns disease and who are homozygous for this NOD2 mutation was substantiated by the finding of decreased anti‐inflammatory cytokine release when cells from these patients were stimulated with different species of Bacteroides, an enteric microorganism implicated in the pathogenesis of Crohns disease. In conclusion, defective NOD2 function results in a pro‐inflammatory cytokine bias after stimulation of mononuclear cells with TLR2 stimuli, and this could contribute to the overwhelming inflammation seen in Crohns disease.


Gut | 2014

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.

Mirthe E. van der Valk; Marie-Josée J. Mangen; Max Leenders; Gerard Dijkstra; Ad A. van Bodegraven; Herma H. Fidder; Dirk J. de Jong; Marieke Pierik; C. Janneke van der Woude; Mariëlle Romberg-Camps; Cees H. Clemens; Jeroen M. Jansen; Nofel Mahmmod; Paul C. van de Meeberg; Andrea E. van der Meulen-de Jong; Cyriel Y. Ponsioen; Clemens J. M. Bolwerk; J. Reinoud Vermeijden; Peter D. Siersema; Martijn G. van Oijen; Bas Oldenburg

Objective The introduction of anti tumour necrosis factor-α (anti-TNFα) therapy might impact healthcare expenditures, but there are limited data regarding the costs of inflammatory bowel diseases (IBD) following the introduction of these drugs. We aimed to assess the healthcare costs and productivity losses in a large cohort of IBD patients. Design Crohns disease (CD) and ulcerative colitis (UC) patients from seven university hospitals and seven general hospitals were invited to fill-out a web-based questionnaire. Cost items were derived from a 3 month follow-up questionnaire and categorised in outpatient clinic, diagnostics, medication, surgery and hospitalisation. Productivity losses included sick leave of paid and unpaid work. Costs were expressed as mean 3-month costs per patients with a 95% CI obtained using non-parametric bootstrapping. Results A total of 1315 CD patients and 937 UC patients were included. Healthcare costs were almost three times higher in CD as compared with UC, €1625 (95% CI €1476 to €1775) versus €595 (95% CI €505 to €685), respectively (p<0.01). Anti-TNFα use was the main costs driver, accounting for 64% and 31% of the total cost in CD and UC. Hospitalisation and surgery together accounted for 19% and <1% of the healthcare costs in CD and 23% and 1% in UC, respectively. Productivity losses accounted for 16% and 39% of the total costs in CD and UC. Conclusions We showed that healthcare costs are mainly driven by medication costs, most importantly by anti-TNFα therapy. Hospitalisation and surgery accounted only for a minor part of the healthcare costs.


Journal of Leukocyte Biology | 2007

Mycobacterium paratuberculosis is recognized by Toll-like receptors and NOD2

Gerben Ferwerda; Bart Jan Kullberg; Dirk J. de Jong; Stephen E. Girardin; Dennis M. L. Langenberg; Reinout van Crevel; Tom H. M. Ottenhoff; Jos W. M. van der Meer; Mihai G. Netea

Mycobacterium paratuberculosis has been suggested to be involved in the pathogenesis of Crohns disease (CD). The importance of microorganisms in CD is supported by the association of CD with mutations in the intracellular pathogen recognition receptor (PRR) nucleotide‐binding oligomerization domain 2 (NOD2). The aim of this study is to investigate the PRR involved in the recognition of M. paratuberculosis. Methods used include in vitro stimulation of transfected cell lines, murine macrophages, and human PBMC. M. paratuberculosis stimulated human TLR2 (hTLR2)‐Chinese hamster ovary (CHO) cells predominantly and hTLR4‐CHO cells modestly. Macrophages from TLR2 and TLR4 knockout mice produced less cytokines compared with controls after stimulation with M. paratuberculosis. TLR4 inhibition in human PBMC reduced cytokine production only after stimulation with live M. paratuberculosis. TLR‐induced TNF‐α, IL‐1β, and IL‐10 production is mediated through MyD88, whereas Toll‐IL‐1R domain‐containing adaptor inducing IFN‐β (TRIF) promoted the release of IL‐1β. hNOD2‐human embryo kidney (HEK) cells, but not hNOD1‐HEK cells, responded to stimulation with M. paratuberculosis. PBMC of individuals homozygous for the 3020insC NOD2 mutation showed a 70% defective cytokine response after stimulation with M. paratuberculosis. These results demonstrate that TLR2, TLR4, and NOD2 are involved in the recognition of M. paratuberculosis by the innate immune system.


Gut | 2009

Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis

Eleonora A. Festen; Philippe Goyette; Regan Scott; Vito Annese; Alexandra Zhernakova; Jing Lian; C Lefebvre; Steven R. Brant; Judy H. Cho; Mark S. Silverberg; Kent D. Taylor; Dirk J. de Jong; Pieter Stokkers; Dermot McGovern; Orazio Palmieri; Jean-Paul Achkar; Ramnik J. Xavier; Mark J. Daly; Richard H. Duerr; Cisca Wijmenga; Rinse K. Weersma; John D. Rioux

Objectives: Genetic susceptibility is known to play a large part in the predisposition to the inflammatory bowel diseases (IBDs) known as Crohn’s disease (CD) and ulcerative colitis (UC). The IL2/IL21 locus on 4q27 is known to be a common risk locus for inflammatory disease (shown in coeliac disease, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus and psoriasis), while the roles that interleukin 2 (IL2) and IL21 play in the immune response also make them attractive candidates for IBD. The objective of this study was to test for association between the IL2/IL21 locus and the IBDs. Methods: The four single nucleotide polymorphisms (SNPs) in the IL2/IL21 locus most associated with coeliac disease were genotyped in 1590 subjects with IBD and 929 controls from The Netherlands, and then replicated in a North American cohort (2387 cases and 1266 controls) and an Italian cohort (805 cases and 421 controls), yielding a total of 4782 cases (3194 UC, 1588 CD) and 2616 controls. Allelic association testing and a pooled analysis using a Cochran–Mantel–Haenszel test were performed. Results: All four SNPs were strongly associated with UC in all three cohorts and reached genome-wide significance in the pooled analysis (rs13151961 p = 1.35×10−10, rs13119723 p = 8.60×10−8, rs6840978 p = 3.07×10−8, rs6822844 p = 2.77×10−9). A moderate association with CD was also found in the pooled analysis (p value range 0.0016–9.86×10−5). Conclusions: A strong association for the IL2/IL21 locus with UC was found, which also confirms it as a general susceptibility locus for inflammatory disease.


Inflammatory Bowel Diseases | 2005

Association between Toll-like receptor 4 and inflammatory bowel disease.

Liekele E. Oostenbrug; Joost P. H. Drenth; Dirk J. de Jong; Ilja M. Nolte; Elvira Oosterom; Hendrik M. van Dullemen; Klaas van der Linde; Gerard J. te Meerman; Gerrit van der Steege; Jan H. Kleibeuker; Peter L. M. Jansen

Background: The human Toll‐like receptor 4 (TLR4) participates in the innate response. Recently, the TLR4 variant Asp299Gly has been described to affect the response of this receptor to lipopolysaccharide. As such, there is a potentially important role of TLR4 in the pathogenesis of inflammatory bowel disease (IBD). We studied the involvement of TLR4 in IBD in a large population of Dutch patients with IBD and in family‐based controls. Methods: In 781 IBD cases and 315 controls, genotyping was performed for Asp299Gly and Thr399Ile variants and for 4 microsatellite markers flanking TLR4. Association analysis and the were applied. In addition, interaction of TLR4 with the caspase recruitment domain containing protein 15 gene (CARD15) was studied in patients with Crohns disease (CD). Results: The haplotype sharing statistic showed association at microsatellite marker D9S1864 with IBD (P = 0.0019), and in particular with CD (P = 0.0025) and at TLR406 with ulcerative colitis (UC; P = 0.027). No association was found for Asp299Gly and Thr399Ile. However, the frequencies of both variant allele carriers were higher among CD cases with a disease onset ≥40 years than among controls. No evidence for interaction between TLR4 and CARD15 was found. Conclusions: Haplotype analysis shows that TLR4 is associated with both CD and UC. The Asp299Gly and Thr399Ile variants do not show an association with CD, UC, or IBD as a group, indicating that these polymorphisms are likely not the causal ones. We propose that the 2 polymorphisms are in linkage with (the) disease susceptibility variant(s) located elsewhere on TLR4.


Journal of Leukocyte Biology | 2006

Impaired dendritic cell function in Crohn's disease patients with NOD2 3020insC mutation.

Matthijs Kramer; Mihai G. Netea; Dirk J. de Jong; Bart Jan Kullberg; Gosse J. Adema

The nucleotide oligomerization domain 2 (NOD2) 3020insC (NOD2fs) mutation increases susceptibility to Crohn’s disease (CD), but the mechanism remains controversial. Loss‐of‐function and gain‐of‐function phenotypes have been described as a result of NOD2fs. Here, we show that dendritic cells (DC) derived from CD patients homozygous for this mutation respond normally to purified Toll‐like receptor (TLR) ligands but fail to up‐regulate the costimulatory molecules CD80 and CD86 in response to the NOD2 ligand muramyl dipeptide (MDP). Moreover, they lack MDP‐induced enhancement of TLR‐mediated tumor necrosis factor α, interleukin (IL)‐12, and IL‐10 production, which is observed in control DC with intact NOD2. These data indicate that the NOD2fs mutation results in a loss‐of‐function phenotype in human myeloid DC and imply decreased immune regulation by IL‐10 as a possible mechanism for this mutation in CD.

Collaboration


Dive into the Dirk J. de Jong's collaboration.

Top Co-Authors

Avatar

Gerard Dijkstra

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Peter D. Siersema

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Christien J. van der Woude

Erasmus University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge